乳腺癌靶向治疗研究进展

Progress of research on targeted therapy for breast cancer

乳腺癌靶向治疗是一种有效的治疗方案,其特异性强,毒副作用小,基本上不损伤正常组织。伴随药理学和分子生物学研究的深入,靶向药物的研究和应用取得了突破性进展,新治疗靶点药物的研发已成为人们关注的热点。本文主要对人类表皮生长因子受体2(HER-2)、哺乳动物雷帕霉素靶蛋白(mTOR)信号通路、血管内皮生长因子(VEGF)、上皮生长因子受体(EGFR)、聚腺苷二磷酸核糖聚合酶(PARP)、周期蛋白依赖性激酶4/6(CDK4/6)为靶点的乳腺癌靶向治疗药物研究进行综述。

Targeted therapy is an effective treatment for breast cancer.The advantages of this therapy are higher specific against tumor cells and less side effects compared to common cytotoxic chemotherapy.In this study,the human epidermal growth factor receptor 2 （HER-2）,mammalian target of rapamycin （mTOR） signaling pathway,vascular endothelial growth factor （VEGF）,epidermal growth factor receptor （EGFR）,poly ADP-ribose polymerase （PARP） and cyclin dependent kinase 4/6 （CDK4/6）,as the target of the breast cancer targeted drug treatment prospective studies were reviewed.